Perrigo’s Mucinex Equivalent On The Cusp, But New Product Outlook Dims

The private labeler’s long-delayed guaifenesin launch now tentatively is set for March, CEO Joseph Papa says. But unclear timelines for other OTC launches caused Perrigo to lower its fiscal year consolidated new product sales outlook to $150 million from an initial projection of more than $190 million.

Perrigo Co. PLC put its long-delayed launch of a Mucinex equivalent on the calendar for March, but the company still downgraded its new product sales expectations for the balance of its fiscal 2013, which ends in June.

More from Marketing & Advertising

More from Compliance